⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALDX News
Aldeyra Therapeutics, Inc.
Form 8-K
sec.gov
ALDX
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
businesswire.com
ALDX
NCQA Launches Advanced Primary Care Pilot Program to Redefine the Future of Primary Care
accessnewswire.com
ALDX
JAZZ
Aldeyra Therapeutics to Participate in the Oppenheimer 36 th Annual Healthcare Life Sciences Conference
businesswire.com
ALDX
Aldeyra Therapeutics to Participate in the Oppenheimer 36 th Annual Healthcare Life Sciences Conference
businesswire.com
ALDX
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
businesswire.com
ALDX
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
businesswire.com
ALDX
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
businesswire.com
ALDX
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
businesswire.com
ALDX